Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Cullen Investment Group LTD.

Cullen Investment Group LTD. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.2% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 15,808 shares of the biopharmaceutical company’s stock after selling 515 shares during the period. Cullen Investment Group LTD.’s holdings in Gilead Sciences were worth $1,460,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in GILD. WINTON GROUP Ltd increased its stake in shares of Gilead Sciences by 52.9% in the second quarter. WINTON GROUP Ltd now owns 8,800 shares of the biopharmaceutical company’s stock worth $604,000 after acquiring an additional 3,043 shares during the last quarter. Greenwich Wealth Management LLC grew its position in shares of Gilead Sciences by 4.0% in the second quarter. Greenwich Wealth Management LLC now owns 7,683 shares of the biopharmaceutical company’s stock valued at $527,000 after purchasing an additional 299 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of Gilead Sciences by 0.6% during the second quarter. Massachusetts Financial Services Co. MA now owns 85,804 shares of the biopharmaceutical company’s stock worth $5,887,000 after buying an additional 522 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Gilead Sciences by 2.6% during the second quarter. Dimensional Fund Advisors LP now owns 10,412,413 shares of the biopharmaceutical company’s stock valued at $714,421,000 after buying an additional 268,208 shares during the last quarter. Finally, Sierra Summit Advisors LLC bought a new stake in shares of Gilead Sciences during the second quarter valued at approximately $783,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Up 0.1 %

GILD stock opened at $89.94 on Tuesday. The business has a fifty day moving average price of $91.94 and a 200-day moving average price of $83.54. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90. The stock has a market capitalization of $112.09 billion, a P/E ratio of 999.33, a P/E/G ratio of 2.24 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter in the previous year, the firm earned $2.29 earnings per share. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. Equities analysts forecast that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.42%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Truist Financial upped their price target on Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research report on Friday, November 8th. Wells Fargo & Company upped their price target on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Citigroup began coverage on shares of Gilead Sciences in a report on Thursday, November 14th. They issued a “buy” rating and a $125.00 price objective on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Finally, UBS Group lifted their price objective on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research note on Thursday, November 21st. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.96.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now directly owns 80,801 shares of the company’s stock, valued at $7,427,227.92. The trade was a 67.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the transaction, the chief financial officer now directly owns 138,919 shares in the company, valued at $12,886,126.44. The trade was a 64.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 453,734 shares of company stock worth $41,902,086 over the last three months. 0.16% of the stock is owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.